Hyung joined Foresite Capital in 2021 as a member of the investment team and focuses on evaluating investment opportunities in private and public biotech companies. Hyung serves as a board member for Latigo Biotherapeutics and a board observer for Odyssey Therapeutics.
Hyung is a physician scientist who joined Foresite Capital from Yale School of Medicine, where he was a tenured faculty member and continues to remain an adjunct faculty. He has published extensively in top scientific and medical journals including Nature, Science, New England Journal of Medicine, Nature Medicine, and Science Translational Medicine, and is an inventor on multiple patents. He has served in multiple academic leadership roles, including as Co-Director of the Yale Cardiovascular Research Center and Director of Translational Research of the Yale Pulmonary Vascular Disease Program, as well as in advisory roles to multiple large pharmaceutical companies and early stage biotechs. He has had continuous funding from the National Institutes of Health throughout his academic career and has been the recipient of multiple honors including the Jeremiah Stamler Distinguished Young Investigator Prize, Irvine H. Page Award from the Amerian Heart Association, election as a Fellow of the American Heart Association, election into the Sir William Osler Interurban Clinical Club, and induction into the American Society for Clinical Investigation.
Hyung received his A.B. with honors in Biochemical Sciences from Harvard College, his M.D. from Johns Hopkins University School of Medicine, completed his internal medicine residency and cardiovascular fellowship at Stanford, and was a visiting scholar at the University of Cambridge. Hyung is a board-certified cardiologist who continues to manage patients with cardiovascular disease.
